Nico Gagelmann jatkaa edelliseen twiittiin
New Approach for High-Risk MDS: BEXMAB Trial Results❗️
Bexmarilimab, a first-in-class macrophage checkpoint inhibitor, shows promising early results in combination with azacitidine for patients with high-risk myelodysplastic syndrome (HR MDS)—a group with few effective options, especially after HMA failure.
Key Highlights:
-
100% response rate in initial frontline MDS patients
-
- 80% ORR in relapsed/refractory (r/r) MDS (65% by updated IWG2023 criteria)
Median OS of 13.4 months in r/r MDS—more than double historical outcomes (<6 months)
- 80% ORR in relapsed/refractory (r/r) MDS (65% by updated IWG2023 criteria)
-
No dose-limiting toxicities in dose escalation
-
Most AEs were manageable; only 13.7% were related to bexmarilimab
-
Doses of 3mg/kg and 6mg/kg being evaluated for optimal efficacy/tolerability
The BEXMAB study offers a potential immunotherapy-based breakthrough for both frontline and r/r HR MDS, patients with urgent unmet need.
Congrats @Dr_AmerZeidan @Daver_Leukemia et al. #leusm #EHA2025